PPGN — PolyPeptide AG Income Statement
0.000.00%
Last trade - 00:00- CH₣821.86m
- CH₣882.73m
- €391.95m
Annual income statement for PolyPeptide AG, fiscal year end - December 31st, EUR millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 286 | 283 | 325 | 339 | 392 |
| Cost of Revenue | |||||
| Gross Profit | 104 | 54.5 | 9.25 | 39.5 | 67.9 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 222 | 271 | 361 | 346 | 383 |
| Operating Profit | 64.2 | 12.6 | -36.5 | -7.36 | 8.69 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 59.8 | 7.57 | -58.2 | -18.1 | -20.1 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 47.3 | 7.77 | -51.4 | -19.6 | -21.2 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 47.3 | 7.77 | -51.4 | -19.6 | -21.2 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 47.3 | 7.77 | -51.4 | -19.6 | -21.2 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 1.47 | 0.234 | -1.5 | -0.561 | -0.533 |
| Dividends per Share |